Verekitug moves toward pivotal trials as Upstream Bio targets quarterly dosing across two respiratory diseases
Upstream Bio sets Phase 3 plans for quarterly verekitug in severe asthma and CRSwNP after FDA discussions. See what the pivotal strategy means.